17 December 2019

Re: Proliant Biologicals, LLC purchases Boval BioSolutions, LLC.

Dear Valued Customer,

As announced on 3 September 2019, Boval BioSolutions, LLC (Boval), a Lifecycle Technologies company based in Cleburne, Texas, was acquired by LGI company Proliant Biologicals, LLC (Proliant), an Ankeny, Iowa based company.

In the months since the acquisition, the Proliant leadership team has determined the best option to ensure long term supply for our customers is to consolidate all manufacturing operations into existing Proliant facilities.

Accordingly, there are “Notifiable” changes that will affect the future manufacturing and purchasing of current Boval BSA product lines once the transition is complete. Chief of these being the cease of manufacturing operations effective **31 December 2020** at the Cleburne manufacturing facility.

<table>
<thead>
<tr>
<th>Current Manufacturing Location</th>
<th>Future Manufacturing Locations (Product Dependent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boval BioSolutions, LLC</td>
<td>Proliant Biologicals, LLC</td>
</tr>
<tr>
<td>505 W Industrial Blvd,</td>
<td>2020 Lakewood Dr,</td>
</tr>
<tr>
<td>Cleburne, TX 76033 USA</td>
<td>Boone, IA 50036 USA</td>
</tr>
<tr>
<td></td>
<td>Proliant New Zealand, Ltd</td>
</tr>
<tr>
<td></td>
<td>33 Kawakawa Road,</td>
</tr>
<tr>
<td></td>
<td>Feilding 4775, New Zealand</td>
</tr>
</tbody>
</table>

Please note the following:

1. Proliant will continue manufacturing operations for the next 12 months (through 31 Dec 2020) with no process and/or product changes.
2. As of 1 January 2021, current Boval products and corresponding part numbers will be discontinued.
3. In the interim, samples from individual lots of the Proliant equivalent SKU will be provided for customer evaluation.

While there will be no process changes for the coming year, Proliant cannot guarantee supply given production limitations at the Cleburne manufacturing facility. With this, the Proliant Technical and BSA Team will provide guidance selecting the equivalent Proliant product SKU to meet your manufacturing requirements.
Further, Proliant has established a Transition Team ensuring all necessary supporting documentation and product qualification samples are in place prior to the 31 December 2020 date.

**Transition Team:**

<table>
<thead>
<tr>
<th>Contact</th>
<th>Title</th>
<th>Item</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyle Hendrickson</td>
<td>Director of Quality Assurance</td>
<td>Quality Questions</td>
<td><a href="mailto:Kyle.Hendrickson@enterahealth.com">Kyle.Hendrickson@enterahealth.com</a> 515-433-4752</td>
</tr>
<tr>
<td>Marshall Franklin</td>
<td>Director of Sales and Marketing</td>
<td>Transition Details</td>
<td><a href="mailto:Marshall.Franklin@proliantinc.com">Marshall.Franklin@proliantinc.com</a> 515-289-5169</td>
</tr>
<tr>
<td>Vic Phillips</td>
<td>International Sales and Marketing Manager</td>
<td>Transition Details</td>
<td><a href="mailto:Vic.Phillips@proliantinc.com">Vic.Phillips@proliantinc.com</a> 435-760-6751</td>
</tr>
<tr>
<td>Dianne Comstock</td>
<td>Global Customer Service Manager</td>
<td>Sample Requests and Orders</td>
<td><a href="mailto:Dianne.Comstock@proliantinc.com">Dianne.Comstock@proliantinc.com</a> 515-433-4740</td>
</tr>
</tbody>
</table>

Proliant understands the acquisition and transition to the equivalent Proliant product SKU will require support throughout the qualification period. We appreciate the opportunity to continue working together and look forward to a long-term collaboration.

Please feel free to contact me with any questions you might have regarding this transition.

If you are not the correct contact, please forward this document to the correct personnel and notify Proliant who the appropriate contact is moving forward.

Kind regards,

___________________
Kyle J. Hendrickson
Director of Quality Assurance
515-433-4752
Plasma production from raw blood through centrifugation at the Slaughterhouse.

Serum production from defibrinated raw blood through centrifugation at the Slaughterhouse.

**LIPID REMOVAL**
Removal of clotting proteins and associated molecules to make serum-like product. Necessary for Proliant to capture and utilize the immunoglobulins in plasma.

**BSA SEPARATION**

**HEAT SHOCK**
Stabilizer protects the BSA at elevated temperatures and is used to denature and purify BSA from other blood proteins.

**PURIFIED BSA SEPARATION**
Purified BSA is separated from the denatured proteins using precipitation and centrifugation.

**MINERAL ASH REMOVAL**

**CONCENTRATION**

**FILTRATION**

**LYOPHILIZATION**
Water removal by lyophilization for powder formulation

**CRUDE BSA SEPARATION**
Crude BSA is separated from the denatured proteins using precipitation and filtration.

**MINERAL ASH REMOVAL**

**CONCENTRATION**

**FILTRATION**